VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
32.19
-0.67 (-2.04%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close32.86
Open32.27
Bid32.10 x 0
Ask32.25 x 0
Day's Range31.78 - 32.56
52 Week Range14.01 - 36.02
Volume1,161,127
Avg. Volume1,169,882
Market Cap11.027B
Beta-2.02
PE Ratio (TTM)4.71
EPS (TTM)6.83
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est21.38
  • MARKETS: Here's why stocks are dropping right now
    Yahoo Finance Video9 days ago

    MARKETS: Here's why stocks are dropping right now

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.

  • CNBCyesterday

    Cramer's lightning round: I don't like Snap's ownership structure

    Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.

  • The woman behind 'female Viagra' sold her company for $1 billion — then got it back for free
    CNBC3 days ago

    The woman behind 'female Viagra' sold her company for $1 billion — then got it back for free

    Cindy Eckert is the anti-Martin Shkreli — after the billion-dollar Valeant debacle, the founder of Sprout Pharmaceuticals is back as CEO and she's slashed the price of the little pink libido pill for women. Here's what she learned from the experience and where she goes from here.

  • Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
    Zacks5 days ago

    Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

    Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

  • Barrons.com5 days ago

    Valeant's FDA Letter: Don't Write Off the Stock Yet

    Shares of Valeant Pharmaceuticals International (VRX) started the week off on a down note, on news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment Monday, and the shares are falling again today. Cantor Fitzgerald argued that the letter wasn't anything for investors to worry about, and today H.C. Wainwright analyst Raghuram Selvaraju argues much the same thing, even if he has a Neutral rating on the stock. Selvaraju writes that although the psoriasis drug, Duobrii, was one of the "Significant Seven" products around which he saw the "new" Valeant would be built, he--much like Cantor--hasn't included sales from the treatment in his model for 2018.

  • Company News For Jun 19, 2018
    Zacks5 days ago

    Company News For Jun 19, 2018

    Companies in the news are: JD,GOOGL,VRX,SLDB,TSLA

  • Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today
    Motley Fool5 days ago

    Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today

    The FDA has dealt the company some disappointing news on one of its late-stage drugs.

  • What Happened in the Stock Market Today
    Motley Fool5 days ago

    What Happened in the Stock Market Today

    On a day stocks fell on trade worries, Google announced a big investment, and Valeant Pharmaceuticals got a rejection from the FDA.

  • Valeant’s Rebound Falters After Key Drug Is Rejected
    Bloomberg6 days ago

    Valeant’s Rebound Falters After Key Drug Is Rejected

    Valeant Pharmaceuticals International Inc.’s rebound from this year’s low in March was stopped in its tracks after U.S. regulators rejected its application for a plaque psoriasis lotion, Duobrii, that management saw as the first of many new drugs to hit the market in the next few years. Trading volume was more than 1.5 times the full-day average of the past three months as investors retreated even after the company pointed out that the Food and Drug Administration’s ruling was related to its pharmacokinetic data and said management is working to “resolve this matter expeditiously” and has already requested a meeting with regulators. Wells Fargo analyst David Maris warned that an approval may be delayed by six to nine months depending on Valeant’s need to generate additional data.

  • Reuters6 days ago

    FDA declines to approve Valeant's plaque psoriasis lotion

    Valeant Pharmaceuticals International Inc's plaque psoriasis treatment did not get approval from U.S. health regulators, a setback for the company which had high hopes for the lotion. A possible delay in approval of the treatment could be a blow to the company, as the treatment is one of the seven products, dubbed as the "Significant Seven", highlighted in Valeant's pipeline projected to raise over $1 billion over the next five years. "We wonder if Valeant will need to update this expectation for the 'Significant Seven' peak sales following the setback to Duobrii," Wells Fargo analyst David Maris said in a note.

  • Barrons.com6 days ago

    FDA Letter May Not Hamper Valeant for Long

    Shares of Valeant Pharmaceuticals International (VRX) are lower on Monday, following news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment. Chen writes that there are three reasons why she still has confidence in Valeant: The fact that the pharmacokinetic (PK) data has been available for "years," that in April, the Journal of American Academy of Dermatology published positive results from two Phase 3 randomized double-blind clinical trials for the first time, and sales of Duobrii wouldn't have been critical to Valeant's 2018 sales, given that it would have launched late in the year.  Chen notes that the FDA's letter related to Duobrii's PK data, and Valeant is working with the agency.

  • The Wall Street Journal6 days ago

    Stocks to Watch: Apple, Facebook, Alphabet, Comcast, GE, GM, Wynn, Valeant, Chevron, Perry Ellis

    Among the companies with shares expected to trade actively in Monday's session are Apple, Facebook, Alphabet, Comcast, General Electric and General Motors.

  • MarketWatch6 days ago

    Valeant shares drop 5% after FDA fails to approve plaque psoriasis lotion

    Valeant Pharmaceuticals International Inc. shares dropped 5.4% in premarket trade on Monday on news that the Food and Drug Administration failed to approve the company's lotion intended to treat plaque psoriasis. In a "complete response letter" notifying the company of the decision, the regulator noted questions about pharmacokinetic data, but did not specify problems with how well the product, Duobrii, works, nor with chemistry, manufacturing and controls processes, the company said. Valeant says it plans to work with the FDA to resolve the matter.

  • PR Newswire6 days ago

    FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion

    LAVAL, Quebec, June 18, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis. The CRL only noted questions regarding pharmacokinetic data," said Joseph C. Papa, chairman and CEO, Valeant. "We are working to resolve this matter expeditiously and have already requested a meeting with the FDA.

  • Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
    Zacks9 days ago

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

  • PR Newswire10 days ago

    Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops

    Now Available at Major U.S. Retailers LAVAL, Quebec , June 14, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International ...

  • What Cindy Eckert has planned with Sprout, Addyi back in hands
    American City Business Journals11 days ago

    What Cindy Eckert has planned with Sprout, Addyi back in hands

    It’s take two for Sprout Pharmaceuticals and Addyi, the only drug approved by the U.S. Food and Drug Administration to treat low sexual desire disorder (HSDD) in women.

  • The Women’s Libido Pill Is Back, and So Is the Controversy
    Bloomberg11 days ago

    The Women’s Libido Pill Is Back, and So Is the Controversy

    This past January, when Cindy Eckert got back the keys to her old office in Raleigh, N.C., she walked into a time capsule. It was the first time Eckert had entered the office since she sold—and was then pushed out of—her company, Sprout Pharmaceuticals Inc. She and her then-husband started the company to bring to market the first drug to enhance female sexual desire. Since that moment, the story of Addyi, the pink pill, has been frozen in time.

  • PR Newswire12 days ago

    Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins

    LAVAL, Quebec, June 12, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the introduction of Ocuvite® Blue Light eye vitamins, a nutritional supplement formulated with lutein and zeaxanthin, the two carotenoid pigments naturally found in the eye. This formulation of eye nutrients includes high levels of lutein and helps protect eyes from the blue light that reaches the macula, which is responsible for our central vision. "With the increasing number of hours Americans are spending on digital devices, there is a growing need for a product that helps our eyes filter the blue light that is emitted from these devices," said Joseph Gordon, president, Consumer Healthcare and Vision Care, Bausch + Lomb.

  • Valeant Pharmaceuticals’ Valuation on June 8
    Market Realist13 days ago

    Valeant Pharmaceuticals’ Valuation on June 8

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.

  • What Are Valeant’s Key Developments since May?
    Market Realist13 days ago

    What Are Valeant’s Key Developments since May?

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a 9% decrease in its operating revenues to ~$2.0 billion during the first quarter—compared to revenues of ~$2.1 billion during the first quarter of 2017. On June 1, Valeant entered into a fourth amended and restated credit and guarantee agreement to refinance its secured revolving and term loan credit facilities. The company also closed the offering of 8.500% senior notes due in 2027 by a wholly owned indirect subsidiary.

  • Analyzing Valeant’s Quarterly Earnings and Estimates
    Market Realist15 days ago

    Analyzing Valeant’s Quarterly Earnings and Estimates

    Valeant Pharmaceuticals (VRX) reported a GAAP net loss of ~$2.7 billion during the first quarter—compared to the GAAP net income of ~$628 million during the first quarter of 2017. Also, the GAAP EPS was negative at -$7.68. The company reported a loss during the first quarter—compared to the GAAP EPS of $1.79 during the first quarter of 2017.

  • Valeant’s Quarterly Revenue Trend and Estimates
    Market Realist16 days ago

    Valeant’s Quarterly Revenue Trend and Estimates

    Valeant Pharmaceutical’s (VRX) revenues decreased ~5.4% to ~$2.0 billion during the first quarter—compared to revenues of ~$2.1 billion during the first quarter of 2017. Valeant met Wall Street analysts’ revenue estimates and reported revenues of ~$1.995 billion—compared to estimates of ~$1.944 billion during the first quarter. Valeant reported organic growth of 2% in total revenues during the first quarter.

  • Analysts’ Recommendations for Valeant in June
    Market Realist16 days ago

    Analysts’ Recommendations for Valeant in June

    Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter.

  • Valeant (VRX) Up 19.3% Since Earnings Report: Can It Continue?
    Zacks17 days ago

    Valeant (VRX) Up 19.3% Since Earnings Report: Can It Continue?

    Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.